case_images: PMC3507315_01
case_images: Molecular structure of sirolimus extracted from KEGG database.
case_images: MI2012-563709.008.jpg
case_images: PMC3507315_01_MI2012-563709.008.jpg
case_images: fig8
case_images: Another widely used macrolide is rapamycin, also known as sirolimus (Figure 8).
case_images: mTOR signaling pathway extracted from KEGG database.
case_images: MI2012-563709.009.jpg
case_images: PMC3507315_01_MI2012-563709.009.jpg
case_images: fig9
case_images: After binding with tacrolimus binding protein (FK-BP) immunophilin, the rapamycin complex inhibits the stimulatory effect of mTOR on cell cycle protein translation, arresting the G1 to S transition (Figure 9).
case_images: Molecular structure of everolimus extracted from KEGG database.
case_images: MI2012-563709.010.jpg
case_images: PMC3507315_01_MI2012-563709.010.jpg
case_images: fig10
case_images: Everolimus (RAD001) is a rapamycin derivative (Figure 10) with potent immunosuppressive effects, antiproliferative properties, and anticancer effects in many preclinical and clinical studies.
case_images: Molecular structure of temsirolimus extracted from KEGG database.
case_images: MI2012-563709.011.jpg
case_images: PMC3507315_01_MI2012-563709.011.jpg
case_images: fig11
case_images: Temsirolimus (CCI-779, Torisel, Wyeth) is another rapamycin derivative (Figure 11) and has properties that are similar to everolimus.
case_images: Molecular structure of ridaforolimus extracted from KEGG database.
case_images: MI2012-563709.012.jpg
case_images: PMC3507315_01_MI2012-563709.012.jpg
case_images: fig12
case_images: Another newly developed molecule is ridaforolimus (also known as deforolimus, AP23473, MK-8669, Merck), a rapamycin analogue (Figure 12), which has broad inhibitory effects on the cell growth, proliferation, division, metabolism, and angiogenesis of a broad panel of cell lines.